Nasdaq · CIK 0001817241
ARTV Artiva Biotherapeutics, Inc.
Insider trading from SEC Form 4. Last filing 5 d ago. Close $6.94 on Oct 9, 2026, +153% from the 52-week low and -48% from the high.
Last 90 days
Net insider value
-$1.9M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
10
$1.9M by 4 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
ARTVOct 9, 2026 · close 6.94
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Artiva Biotherapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Fred Aslan Chief Executive Officer sell | $169k 23,463 shares | -2% | +165% from low-46% from high | |
| 56Moderate | Fred Aslan Chief Executive Officer sell | $422k 61,696 shares | -4% | +160% from low-47% from high | |
| 30Weak | Subhashis Banerjee Chief Medical Officer sell | $7,514 1,099 shares | -1% | +160% from low-47% from high | |
| 42Moderate | Jennifer Bush COO, CLO, Compliance Officer sell | $57k 8,370 shares | -2% | +160% from low-47% from high | |
| 38Weak | Christopher Horan Chief Tech Operations Officer sell | $71k 10,340 shares | -3% | +160% from low-47% from high | |
| 33Weak | Fred Aslan Chief Executive Officer sell | $256k 23,429 shares | -2% | - | |
| 61Notable | Fred Aslan Chief Executive Officer sell | $690k 61,888 shares | -4% | - | |
| 30Weak | Subhashis Banerjee Chief Medical Officer sell | $12k 1,100 shares | -1% | - | |
| 45Moderate | Jennifer Bush COO, CLO, Compliance Officer sell | $94k 8,391 shares | -2% | - | |
| 40Moderate | Christopher Horan Chief Tech Operations Officer sell | $116k 10,366 shares | -4% | - |
Transactions
The last 53 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Fred Aslan Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -23,463 | $7.20 | $169k | 1,519,606 | 5 d ago |
| Oct 5, 2026 | Fred Aslan Chief Executive Officer | SOpen-market sale Common Stock | -61,696 | $6.84 | $422k | 1,543,069 | 6 d ago |
| Oct 5, 2026 | Subhashis Banerjee Chief Medical Officer | SOpen-market sale Common Stock | -1,099 | $6.84 | $7,514 | 169,848 | 6 d ago |
| Oct 5, 2026 | Jennifer Bush COO, CLO, Compliance Officer | SOpen-market sale Common Stock | -8,370 | $6.84 | $57k | 366,159 | 6 d ago |
| Oct 5, 2026 | Christopher Horan Chief Tech Operations Officer | SOpen-market sale Common Stock | -10,340 | $6.84 | $71k | 312,744 | 6 d ago |
| Sep 15, 2026 | Fred Aslan Chief Executive Officer | AGrant or award Common Stock | +110,000 | $0.00 | $0 | 1,604,765 | 27 d ago |
| Sep 15, 2026 | Fred Aslan Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +315,000 | $0.00 | $0 | 315,000 | 27 d ago |
| Sep 10, 2026 | Alison Moore director | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 10, 2026 | Daniel G. Baker director | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 10, 2026 | Brian Daniels director | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 10, 2026 | Elizabeth L Hougen director | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 10, 2026 | Elaine K. Sorg director | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 10, 2026 | Laura Stoppel director | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 10, 2026 | Fred Aslan Chief Executive Officer | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 1,494,765 | 28 d ago |
| Sep 10, 2026 | Ra Capital Management, L.p. director, owner | AGrant or award Director Stock Option (Right to Buy)derivativeindirect: See Footnotes | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 10, 2026 | Fred Aslan Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +155,000 | $0.00 | $0 | 155,000 | 28 d ago |
| Sep 9, 2026 | Subhashis Banerjee Chief Medical Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 170,947 | 31 d ago |
| Sep 9, 2026 | Jennifer Bush COO, CLO, Compliance Officer | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 374,529 | 31 d ago |
| Sep 9, 2026 | Christopher Horan Chief Tech Operations Officer | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 323,084 | 31 d ago |
| Sep 9, 2026 | Gines Diego Miralles President & Head of R&D | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 122,500 | 31 d ago |
| Sep 9, 2026 | Subhashis Banerjee Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +85,000 | $0.00 | $0 | 85,000 | 31 d ago |
| Sep 9, 2026 | Jennifer Bush COO, CLO, Compliance Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +135,000 | $0.00 | $0 | 135,000 | 31 d ago |
| Sep 9, 2026 | Christopher Horan Chief Tech Operations Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | 31 d ago |
| Sep 9, 2026 | Gines Diego Miralles President & Head of R&D | AGrant or award Employee Stock Option (Right to Buy)derivative | +135,000 | $0.00 | $0 | 135,000 | 31 d ago |
| Sep 8, 2026 | Fred Aslan Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -23,429 | $10.92 | $256k | 1,449,765 | 33 d ago |
| Sep 8, 2026 | Ra Capital Management, L.p. director, owner | AGrant or award Director Stock Option (Right to Buy)derivativeindirect: See Footnotes | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Sep 8, 2026 | Brian Daniels director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Sep 8, 2026 | Laura Stoppel director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Sep 8, 2026 | Elizabeth L Hougen director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Sep 8, 2026 | Daniel G. Baker director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Sep 8, 2026 | Alison Moore director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Sep 8, 2026 | Elaine K. Sorg director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Sep 3, 2026 | Fred Aslan Chief Executive Officer | SOpen-market sale Common Stock | -61,888 | $11.16 | $690k | 1,473,194 | 38 d ago |
| Sep 3, 2026 | Subhashis Banerjee Chief Medical Officer | SOpen-market sale Common Stock | -1,100 | $11.16 | $12k | 140,947 | 38 d ago |
| Sep 3, 2026 | Jennifer Bush COO, CLO, Compliance Officer | SOpen-market sale Common Stock | -8,391 | $11.16 | $94k | 329,529 | 38 d ago |
| Sep 3, 2026 | Christopher Horan Chief Tech Operations Officer | SOpen-market sale Common Stock | -10,366 | $11.16 | $116k | 283,084 | 38 d ago |
| Jun 24, 2025 | Alison Moore director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 24, 2025 | Ra Capital Management, L.p. director, owner | AGrant or award Director Stock Option (Right to Buy)derivativeindirect: See Footnotes | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 24, 2025 | Laura Stoppel director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 24, 2025 | Daniel G. Baker director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 24, 2025 | Elizabeth L Hougen director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 24, 2025 | Gines Diego Miralles President & Head of R&D | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 24, 2025 | Brian Daniels director | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Apr 8, 2025 | Subhashis Banerjee Chief Medical Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 50,000 | Apr 25, 2025 |
| Apr 8, 2025 | Subhashis Banerjee Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Apr 25, 2025 |
| Mar 5, 2025 | Fred Aslan President and CEO | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 416,665 | Mar 7, 2025 |
| Feb 26, 2025 | Jennifer Bush COO, CLO, Secy, Compliance Off | AGrant or award Common Stock | +86,650 | $0.00 | $0 | 159,449 | Feb 28, 2025 |
| Feb 26, 2025 | Neha Krishnamohan Chief Financial Officer | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 110,000 | Feb 28, 2025 |
| Feb 26, 2025 | Christopher Horan Chief Tech Operations Officer | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 85,000 | Feb 28, 2025 |
| Feb 26, 2025 | Thorsten Graef Chief Medical Officer | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 80,000 | Feb 28, 2025 |
| Feb 26, 2025 | Heather Raymon SVP, Research and Development | AGrant or award Common Stock | +33,350 | $0.00 | $0 | 43,350 | Feb 28, 2025 |
| Jan 28, 2025 | Daniel G. Baker director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,500 | $0.00 | $0 | 27,500 | Jan 29, 2025 |
| Oct 21, 2024 | Alison Moore director | AGrant or award Director Stock Option (Right to Buy)derivative | +27,500 | $0.00 | $0 | 27,500 | Oct 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Fred AslanChief Executive Officer
- Daniel G. Bakerofficer, director
- Subhashis BanerjeeChief Medical Officer
- Jennifer BushCOO, CLO, Compliance Officer
- Brian Danielsdirector
- Thorsten GraefChief Medical Officer
- Elizabeth L Hougencfo, officer, director
- Christopher HoranChief Tech Operations Officer
- Neha KrishnamohanChief Financial Officer
- Alison Mooredirector, officer
- Gines Diego MirallesPresident & Head of R&D
- Ra Capital Management, L.p.owner, director
- Heather RaymonSVP, Research and Development
- Elaine K. Sorgdirector
- Laura Stoppeldirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.